USPSTF Recommendations on Genetic Testing for Breast Cancer
Yes, the USPSTF does make specific recommendations regarding genetic testing for breast cancer—specifically for BRCA1/2 mutations—with a risk-stratified approach based on family history and ancestry. 1
The Two-Tiered Recommendation
The USPSTF provides clear guidance with both a positive and negative recommendation:
B Recommendation (Recommended):
Primary care providers should screen women with a family history of breast, ovarian, tubal, or peritoneal cancer—or those with ancestry associated with BRCA1/2 mutations—using validated risk assessment tools. Women who screen positive should receive genetic counseling and, if indicated after counseling, BRCA testing. 1, 2
D Recommendation (Recommended Against):
The USPSTF recommends against routine genetic counseling or BRCA testing for women whose family or personal history is NOT associated with increased risk for BRCA1/2 mutations. This is a firm recommendation against universal screening. 1
Who Should Be Screened
The recommendation applies to:
- Asymptomatic women who have never been diagnosed with BRCA-related cancer
- Women with completed treatment for breast, ovarian, tubal, or peritoneal cancer who are now cancer-free 2
- Women with specific family history patterns suggesting hereditary risk
- Women of Ashkenazi Jewish ancestry (higher prevalence of specific BRCA mutations) 2
Validated Risk Assessment Tools
The USPSTF endorses several brief familial risk assessment tools for primary care use, though it found insufficient evidence to recommend one over another 1:
- Family History Screen-7 (FHS-7) - simplest and quickest
- Referral Screening Tool (B-RST) - simple and quick
- Ontario Family History Assessment Tool
- Manchester Scoring System
- Pedigree Assessment Tool
Key red flags these tools identify:
- Breast cancer diagnosis before age 50
- Bilateral breast cancer
- Both breast and ovarian cancer in family
- Male breast cancer in family
- Multiple breast cancers in family
- Ashkenazi Jewish ethnicity 1
Critical Implementation Gap
Important caveat: Despite this being a decade-old recommendation (originally issued in 2005, reaffirmed in 2014, updated in 2019), implementation remains poor. Only 9.5% of screen-positive women report discussing genetic testing with providers, and only 2.7% actually undergo testing 3. This represents a significant quality gap in preventive care.
What NOT to Use
Do not use general breast cancer risk assessment tools (like the Gail model/NCI Breast Cancer Risk Assessment Tool) for determining who needs genetic counseling—these are designed for general breast cancer risk, not hereditary risk assessment. 1
The Rationale
The USPSTF concludes with moderate certainty that for women with increased familial risk, the net benefit of testing, detection, and early intervention is moderate. Conversely, for women without increased risk, the net benefit ranges from minimal to potentially harmful (due to false positives, anxiety, and unnecessary interventions). 1